Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted, Proteomic-guided Systemic Therapy in Advanced NSCLC
NCT07250477Phase 2Recruiting
- Sponsor
- University of California, Davis
- Start
- Jan 2026
- Primary completion
- May 2036
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University of California, Davis. Primary endpoint: 12-month Progression-Free Survival. Started Jan 2026; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07250477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07250477.